IFNB1 and neoplasm: Although no therapeutic benefit of AdV-tk and Ad.IFNα was appreciated in these advanced tumor settings, previous work with Ad.IFNβ has suggests that immunotherapy still generates CD8 T-cells capable of tumor neutralization [14].